The power of prostacyclin delivered with ease The power of prostacyclin delivered with ease

The Power of Prostacyclyn Delivered with Ease

YUTREPIA is the first and only inhaled prostacyclin enabled by PRINT® Technology

Enhanced deep-lung delivery2
See the difference
Ease of use with a low-effort device2-5,*
See the difference
Titration to higher therapeutic doses1,2
Explore data

Defined as low inspiratory effort.4,5

WHO = World Health Organization

References

  1. YUTREPIA. Prescribing information. Liquidia Technologies, Inc; 2025.
  2. Hill NS, Feldman JP, Sahay S, et al; INSPIRE study investigators. INSPIRE: safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH). Pulm Circ. 2022;12(3):e12119. doi:10.1002/pul2.12119
  3. Patel S, Prabel J, MacLennan D, Rosen G. Robustness of YUTREPIA™, a dry-powder inhaled formulation of treprostinil, in patient misuse scenarios. Poster presented at: CHEST 2022 Annual Meeting; October 16-19, 2022; Nashville, TN.
  4. Price D, Chrystyn H. Concept review of dry powder inhalers: correct interpretation of published data. Multidiscip Respir Med. 2015;10:36. doi:10.1186/s40248-015-0033-0
  5. National Health Service Sunderland. Sunderland COPD Inhaler Guide. National Health Service; 2020.